$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

$ytenq Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000110465914039162 Filed on May 15, 2014

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$613.0K	$1.251M
YoY Change	-51.0%	-96.82%
Cost Of Revenue	$166.0K	$557.0K
YoY Change	-70.2%	912.73%
Gross Profit	$447.0K	$694.0K
YoY Change	-35.59%	-98.23%
Gross Profit Margin	72.92%	55.48%
Selling, General & Admin	$3.132M	$3.312M
YoY Change	-5.43%	-16.78%
% of Gross Profit	700.67%	477.23%
Research & Development	$4.810M	$4.860M
YoY Change	-1.03%	-19.67%
% of Gross Profit	1076.06%	700.29%
Depreciation & Amortization	$191.0K	$295.0K
YoY Change	-35.25%	-22.16%
% of Gross Profit	42.73%	42.51%
Operating Expenses	$3.132M	$3.312M
YoY Change	-5.43%	-66.95%
Operating Profit	-$7.491M	-$6.731M
YoY Change	11.29%	-123.35%
Interest Expense	$5.000K	$10.00K
YoY Change	-50.0%	-41.18%
% of Operating Profit
Other Income/Expense, Net	$6.000K	$22.00K
YoY Change	-72.73%
Pretax Income	-$7.490M	-$6.760M
YoY Change	10.8%	-123.44%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$8.154M	-$6.760M
YoY Change	20.62%	-123.44%
Net Earnings / Revenue	-1330.18%	-540.37%
Basic Earnings Per Share	-$0.23	-$0.20
Diluted Earnings Per Share	-$0.23	-$0.20
COMMON SHARES
Basic Shares Outstanding	34.81M shares	34.35M shares
Diluted Shares Outstanding	34.81M shares	34.35M shares

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.40M	$37.70M
YoY Change	-72.41%	-42.88%
Cash & Equivalents	$3.606M	$20.51M
Short-Term Investments	$6.800M	$17.20M
Other Short-Term Assets	$1.100M	$700.0K
YoY Change	57.14%	0.0%
Inventory	$3.756M	$3.624M
Prepaid Expenses
Receivables	$446.0K	$777.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$16.01M	$43.75M
YoY Change	-63.4%	-37.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$456.0K	$1.120M
YoY Change	-59.29%	-44.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00
YoY Change
Other Assets	$95.00K	$95.00K
YoY Change	0.0%	-86.43%
Total Long-Term Assets	$1.414M	$1.809M
YoY Change	-21.84%	-33.0%
TOTAL ASSETS
Total Short-Term Assets	$16.01M	$43.75M
Total Long-Term Assets	$1.414M	$1.809M
Total Assets	$17.43M	$45.56M
YoY Change	-61.75%	-37.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$505.0K	$92.00K
YoY Change	448.91%	-54.0%
Accrued Expenses	$2.616M	$2.679M
YoY Change	-2.35%	-0.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.905M	$3.908M
YoY Change	-0.08%	18.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$148.0K	$134.0K
YoY Change	10.45%	-55.33%
Total Long-Term Liabilities	$148.0K	$134.0K
YoY Change	10.45%	-55.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.905M	$3.908M
Total Long-Term Liabilities	$148.0K	$134.0K
Total Liabilities	$4.053M	$4.056M
YoY Change	-0.07%	12.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$280.7M	-$248.8M
YoY Change	12.82%
Common Stock	$349.0K	$290.3M
YoY Change	-99.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.38M	$41.51M
YoY Change
Total Liabilities & Shareholders Equity	$17.43M	$45.56M
YoY Change	-61.75%	-37.67%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$8.154M	-$6.760M
YoY Change	20.62%	-123.44%
Depreciation, Depletion And Amortization	$191.0K	$295.0K
YoY Change	-35.25%	-22.16%
Cash From Operating Activities	-$8.965M	-$8.500M
YoY Change	5.47%	-30.67%
INVESTING ACTIVITIES
Capital Expenditures	$100.0K	$64.00K
YoY Change	56.25%	-56.76%
Acquisitions
YoY Change
Other Investing Activities	$4.700M	$14.51M
YoY Change	-67.61%	1915.28%
Cash From Investing Activities	$4.600M	$14.44M
YoY Change	-68.14%	2433.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	300.0K	10.00K
YoY Change	2900.0%	0.0%
NET CHANGE
Cash From Operating Activities	-$8.965M	-8.500M
Cash From Investing Activities	4.600M	14.44M
Cash From Financing Activities	300.0K	10.00K
Net Change In Cash	-$8.965M	5.950M
YoY Change	-250.67%	-150.94%
FREE CASH FLOW
Cash From Operating Activities	-$8.965M	-$8.500M
Capital Expenditures	$100.0K	$64.00K
Free Cash Flow	-$9.065M	-$8.564M
YoY Change	5.85%	-30.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001121702
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	METABOLIX, INC.
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34993744	shares
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3606000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7698000	USD
CY2014Q1	us-gaap	Short Term Investments ShortTermInvestments	6812000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	11511000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	3756000	USD
CY2013Q1	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	49000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4892000	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1943000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	557000	USD
CY2014Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	14000	USD
CY2013Q1	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	4859000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3312000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95000	USD
CY2014Q1	us-gaap	Assets Assets	17428000	USD
CY2013Q4	us-gaap	Assets Assets	26738000	USD
CY2013Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	51000	USD
CY2013Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	187000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	713000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	4074000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	446000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	997000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	16014000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1147000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	619000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	619000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	700000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	793000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	505000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	579000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2616000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	8728000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	55000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	770000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	669000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3905000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6195000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	539000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	148000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	145000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	4053000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	6340000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	349000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	292661000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-98000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280692000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-272538000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	13375000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	20398000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17428000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26738000	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34889055	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34581449	shares
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	790000	USD
CY2013Q1	us-gaap	Revenue From Grants RevenueFromGrants	724000	USD
CY2013Q1	mblx	Research And Development Revenue ResearchAndDevelopmentRevenue	380000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6785000	USD
CY2013Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	10000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22000	USD
CY2014Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6763000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	300000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8154000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	695000	USD
CY2014Q1	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	4900000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3634000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	9229000	USD
CY2014Q1	us-gaap	Revenue From Grants RevenueFromGrants	467000	USD
CY2014Q1	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	63000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34806797	shares
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34806797	shares
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34353277	shares
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34353277	shares
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-26000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8181000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-15000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6785000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	191000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	295000	USD
CY2013Q1	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	180000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	863000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	420000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-62000	USD
CY2013Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	561000	USD
CY2013Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-75000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	18000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1141000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-937000	USD
CY2013Q1	mblx	Increase Decrease In Deferred Rent And Long Term Liabilities IncreaseDecreaseInDeferredRentAndLongTermLiabilities	-38000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-95000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8498000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8965000	USD
CY2014Q1	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	169000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	785000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-318000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-551000	USD
CY2014Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	60000	USD
CY2014Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-51000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	434000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-74000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2371000	USD
CY2014Q1	mblx	Increase Decrease In Deferred Rent And Long Term Liabilities IncreaseDecreaseInDeferredRentAndLongTermLiabilities	-38000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	101000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64000	USD
CY2013Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5015000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	19520000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	300000	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-25000	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-8000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-4092000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	5940000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14572000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	14441000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100000	USD
CY2014Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1508000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	6206000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4598000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7480926	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5741056	shares
CY2014Q1	us-gaap	Investments And Cash InvestmentsAndCash	10418000	USD
CY2014Q1	mblx	Period Over Which Capital Resources Are Not Sufficient To Fund Planned Operations PeriodOverWhichCapitalResourcesAreNotSufficientToFundPlannedOperations	P12M
CY2014Q1	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 26pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></p> <p style="TEXT-INDENT: 26pt; MARGIN: 0in 0in 0pt;"> </p> </div>
CY2014Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Concentration of Credit Risk</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company primarily invests its excess cash and cash equivalents in money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.</font></p> <p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary. At March 31, 2014, the Company’s accounts and unbilled receivables include $284 or 41% from U.S. and Canadian government grants and $409 or 59% from customer product sales. At March 31, 2014, the Company’s REFABB grant with the Department of Energy represented 34% of total receivables.</font></p> <p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">At December 31, 2013, the Company’s worldwide accounts and unbilled receivables include $552 or 46% from government grants and $528 or 44% from customer product sales. At December 31, 2013, the Company’s REFABB grant with the Department of Energy represented 56% of total receivables.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> </div>
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	537000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3537000	USD
CY2014Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	929000	USD
CY2014Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2000	USD
CY2014Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2825000	USD
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	476000	USD
CY2014Q1	us-gaap	Deferred Revenue DeferredRevenue	413000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11510000	USD
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	6811000	USD
CY2013Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1000	USD
CY2014Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1000	USD
CY2013Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	11511000	USD
CY2014Q1	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	6812000	USD
CY2013	mblx	Available For Sale Securities Average Maturity AvailableForSaleSecuritiesAverageMaturity	P2M
CY2014Q1	mblx	Available For Sale Securities Average Maturity AvailableForSaleSecuritiesAverageMaturity	P2M
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2595000	USD
CY2013Q4	mblx	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	815000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	578000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	904000	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1573000	USD
CY2014Q1	mblx	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	138000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	370000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	535000	USD
CY2014Q1	us-gaap	Segment Reporting Information Revenue SegmentReportingInformationRevenue	1069000	USD
CY2013Q1	us-gaap	Segment Reporting Information Revenue SegmentReportingInformationRevenue	1943000	USD
CY2014Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2014Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2014Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2014Q1	mblx	Maximum Period To Audit For Loss MaximumPeriodToAuditForLoss	P3Y
CY2013Q4	mblx	Operating Loss Carryforwards Attributable To Deduction Related To Exercise Of Stock Options OperatingLossCarryforwardsAttributableToDeductionRelatedToExerciseOfStockOptions	19213000	USD
CY2014Q1	mblx	Provision For Income Taxes For Undistributed Earnings Of Foreign Subsidiaries ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries	0	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	0	USD
CY2012Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	252000	USD
CY2013Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	273000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2013Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2012	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	38885000	USD
CY2014Q1	mblx	Number Of Major Customers NumberOfMajorCustomers	1	item
CY2013Q1	mblx	Number Of Major Customers NumberOfMajorCustomers	0	item

Files In Submission

Name	View Source	Status
0001104659-14-039162-index-headers.html	Edgar Link	pending
0001104659-14-039162-index.html	Edgar Link	pending
0001104659-14-039162.txt	Edgar Link	pending
0001104659-14-039162-xbrl.zip	Edgar Link	pending
a14-9691_110q.htm	Edgar Link	pending
a14-9691_1ex10d13.htm	Edgar Link	pending
a14-9691_1ex10d14.htm	Edgar Link	pending
a14-9691_1ex31d1.htm	Edgar Link	pending
a14-9691_1ex31d2.htm	Edgar Link	pending
a14-9691_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mblx-20140331.xml	Edgar Link	completed
mblx-20140331.xsd	Edgar Link	pending
mblx-20140331_cal.xml	Edgar Link	unprocessable
mblx-20140331_def.xml	Edgar Link	unprocessable
mblx-20140331_lab.xml	Edgar Link	unprocessable
mblx-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

2014 Q1 Form 10-Q Financial Statement

#000110465914039162 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ YIELD10 BIOSCIENCE, INC. Stock $ytenq

2014 Q1 Form 10-Q Financial Statement

#000110465914039162 Filed on May 15, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq